Therefore, the analysis of CTLs as well as B7‐1 status in primary tumor tissues could provide further information as to the necessity of evaluating PD‐L1 status in metastasis or liquid biopsy when applicable in order to improve the therapeutic efficacy of PD‐1/PD‐L1 inhibitors in NSCLC patients. The gene discussed is CD80; the disease is non-small cell lung carcinoma.